Previous 10 | Next 10 |
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of rec...
– Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstra...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Associ...
2024-05-03 12:47:06 ET Summary Vir Biotechnology, Inc. reported its first-quarter earnings after the bell on Thursday, giving its shareholders some positive tidbits. The company continues to have a cash balance higher than the stock's market capitalization and has some potential u...
2024-05-03 00:35:24 ET Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Conference Call May 02, 2024, 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carri...
2024-05-02 16:25:03 ET More on Vir Biotechnology Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript Vir Biotechnology GAAP EPS of -$0.86 beats by $0.15, revenue of $16.79M beats by $10....
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 b...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the ...
Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. ...
News, Short Squeeze, Breakout and More Instantly...
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that ...
2024-06-05 19:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VIR on June 5, 2024 05:15PM ET. The previous analyst recommendation was Equal-Weight. VIR was trading at $12.66 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-05 17:00:05 ET Michael Ulz from Morgan Stanley issued a price target of $15.00 for VIR on 2024-06-05 14:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VIR was trading at $12.66. The overall price target consensus is at $30.13...